Tuesday, May 21, 2019 – Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI at the 2019 Africa Health: Digital Health Conference on May 28.
The increased availability of data and recent advancements in Artificial Intelligence (AI) present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators.
Benefiting from the increasing availability of useful data, advancements in AI help to reduce costs of drug discovery, bringing vital drugs faster to the market. There are many regions where these transformations are needed, including Africa, where approximately 70% of all pharmaceuticals are imported from other countries, which has not been quite sustainable.
Artificial intelligence techniques help to make great contribution to the pharma industry in Africa, as well as tackle more local health challenges while creating more employment opportunities for the many scientists who could be employed to work towards better and more affordable healthcare solutions for all.
The presentation will cover the latest advances in artificial intelligence and blockchain technologies that accelerate the biomedical research and enable patients to control and benefit from their medical data, that might serve as an incentive to undergo constant health monitoring in Africa.
“We are happy to present our latest research at the 2019 Africa Health Conference, which gathers the leading industry leaders. The topic of artificial intelligence in healthcare is extremely important for the countries located in Africa, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area,” said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant at Insilico Medicine.
Africa Health is the largest gathering of healthcare companies, technology, products and services in the continent. Taking place from 28 – 30 of May 2019, the event is expected to welcome more than 560 exhibiting companies and 10,500 attendees from more than 40 countries.
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/